Updates in immunotherapy for hepatocellular carcinoma
作者机构：Medical OncologySão Paulo Clínicas Liver Cancer GroupHospital das Clínicas ComplexInstituto do Cancer do Estado de São PauloUniversity of São Paulo School of MedicineSão PauloSP 05403-000Brazil Department of GastroenterologySão Paulo Clínicas Liver Cancer GroupHospital das Clínicas ComplexInstituto do Cancer do Estado de São PauloUniversity of São Paulo School of MedicineSão PauloSP 05403-000Brazil
出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)
年 卷 期：2019年第5卷第10期
页 面：19-31页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatocellular carcinoma immunotherapy immunosuppression prognosis immunology antibody vaccine
摘 要：Hepatocellular carcinoma(HCC)carries an unfavorable prognosis and novel therapeutic strategies are *** now,only few systemic agents have improved survival in patients with advanced stage *** changed the landscape in several tumor types by producing unprecedented clinical outcomes with a favorable safety *** presents a particular immune-suppressive microenvironment and HCC develops in a background of chronic inflammation in the vast majority of *** this regard,immunotherapy may be a suitable *** research focused on therapies involving immune cells and anti-tumor immune response for HCC has shown encouraging preliminary *** checkpoint inhibitors,such the anti-PD-1/PD-L1 monoclonal antibodies,have provided durable responses in patients with advanced stage disease,although the pioneers phaseⅢtrials did not confirm survival superiority over the available *** vaccines,adoptive cellular therapies and combinations of local modalities with immunotherapy are promising approaches under active research.
维普期刊数据库